Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

Amendments to Claims

Claims 1-4 (Canceled)

5. (Previously presented): A DNA fragment comprising a nucleic acid sequence according to claim 25.

6. (Previously presented): A recombinant DNA molecule comprising a nucleic acid sequence according to claim 25, under the control of a functionally linked promoter.

7. (Previously presented): A live recombinant carrier comprising a nucleic acid sequence according to claim 25.

8. (Previously presented): A host cell comprising a nucleic acid sequence according claim 25.

Claims 9-18 (canceled)

19. (Previously presented): A vaccine for combating *Brachyspira hyodysenteriae* infection comprising antibodies against a lipoprotein according to claim 29, and a pharmaceutically acceptable carrier.

Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

- 20. (Previously presented): The vaccine according to claim 19, comprising an adjuvant.
- 21. (Previously presented): The vaccine according to claim 19, comprising an additional antigen derived from another swine pathogen, an antibody against such an antigen or genetic information encoding said antigen.
- 22. (Previously presented): The vaccine according to claim 21, wherein said pathogen is selected from the group consisting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.

Claim 23 (Cancel)

24. (Currently amended): A diagnostic kit for detecting Brachyspira

hyodysenteriae or antibodies thereto, comprising a nucleic acid sequence

according to claim 25, or a an immunogenic 61kD Brachyspira

hyodysenteriae lipoprotein, as measured by SDS-PAGE, or antigenic fragment thereof encoded by said sequence, or antibodies that are reactive with said lipoprotein.

Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

- 25. (Previously presented): A nucleic acid sequence encoding an immunogenic 61kD

 Brachyspira hyodysenteriae lipoprotein, as measured by SDS-PAGE.
- 26. (Previously presented): The nucleic acid sequence of claim 25, wherein the 61 kD *Brachyspira hyodysenteriae* lipoprotein has the amino acid sequence of SEQ ID NO:2.
- 27. (Previously presented): A nucleic acid sequence encoding an immunogenic 20kD *Brachyspira hyodysenteriae* lipoprotein, as measured by SDS-PAGE.
- 28. (Previously presented): The nucleic acid sequence of claim 27, wherein the 20 kD *Brachyspira hyodysenteriae* lipoprotein has the amino acid sequence of SEQ ID NO:4.
- 29. (Currently amended): An isolated <u>and purified</u> immunogenic *Brachyspira*hyodysenteriae lipoprotein of 61 kD, as measured by SDS-PAGE.
- 30. (Currently amended): The isolated <u>and purified</u> immunogenic *Brachyspira*hyodysenteriae lipoprotein of claim 29 having the amino acid sequence of SEQ

 ID NO: 2.
- 31. (Previously presented): An isolated immunogenic *Brachyspira hyodysenteriae* lipoprotein of 20 kD, as measured by SDS-PAGE.

Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

- 32. (Previously presented): The isolated immunogenic *Brachyspira hyodysenteriae* lipoprotein of claim 31 having the amino acid sequence of SEQ ID NO:4.
- 33. (Currently amended): An immunogenic composition comprising an immunogenically effective amount of the *Brachyspira hyodysenteriae* lipoprotein of claim 29 and a pharmaceutically acceptable carrier.
- 34. (Previously presented): An immunogenic composition comprising an effective amount of the *Brachyspira hyodysenteriae* lipoprotein of claim 31 and a pharmaceutically acceptable carrier.
- 35. (Previously presented): An immunogenic composition comprising an immunogenically effective amount of a nucleic acid sequence selected from the group consisting of a DNA fragment, a recombinant DNA molecule and a live recombinant carrier, or host cell comprising said nucleic acid sequence, wherein said nucleic acid sequence is the nucleic acid sequence of claim 25.
- 36. (Previously presented): An immunogenic composition comprising an immunogenically effective amount of a nucleic acid sequence selected from the group consisting of a DNA fragment, a recombinant DNA molecule and a live recombinant carrier, or a host cell comprising said nucleic sequence, wherein said nucleic acid sequence is the nucleic acid sequence of claim 27.

Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

- 37. (Previously presented): A DNA fragment comprising a nucleic acid sequence according to claim 27.
- 38. (Previously presented): A recombinant DNA molecule comprising a nucleic acid sequence according to claim 27, under the control of a functionally linked promoter.
- 39. (Previously presented): A live recombinant carrier comprising a nucleic acid sequence according to claim 27.
- 40. (Previously presented): A host cell comprising a nucleic acid sequence according to claim 27.
- 41. (Previously presented): A diagnostic kit for detecting *Brachyspira*hyodysenteriae or antibodies thereto, comprising a nucleic acid sequence
 according to claim 27, or a lipoprotein or antigenic fragment thereof encoded by
 said sequence, or antibodies that are reactive with said lipoprotein.
- 42. (Previously presented): A vaccine for combating *Brachyspira hyodysenteriae* infection, comprising antibodies against a lipoprotein according to claim 31 and a pharmaceutically acceptable carrier.
- 43. (Previously presented): The vaccine according to claim 42, comprising an Page 6 of 9

Attorney Docket: 2002.011 US

Amendment and Reply Restriction Requirement of September 28, 2006

adjuvant.

- 44. (Previously presented): The vaccine according to claim 42, comprising an additional antigen derived from another swine pathogen, an antibody against such an antigen or genetic information encoding said antigen.
- 45. (Previously presented): The vaccine according to claim 44, wherein said pathogen is selected from the group constituting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae.
- 46. **(New):** A method for protecting swine against a *Brachyspira hyodysenteriae*, comprising administering an immunogenically effective amount of the immunogenic composition of claim 33.
- 47. **(New):** A method for protecting swine against *Brachyspira hyodysenteriae*, comprising administering an immunogenically effective amount of the lipoprotein of claim 30.